1. Home
  2. CRSP vs ALHC Comparison

CRSP vs ALHC Comparison

Compare CRSP & ALHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • ALHC
  • Stock Information
  • Founded
  • CRSP 2013
  • ALHC 2013
  • Country
  • CRSP Switzerland
  • ALHC United States
  • Employees
  • CRSP N/A
  • ALHC N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • ALHC Medical Specialities
  • Sector
  • CRSP Health Care
  • ALHC Health Care
  • Exchange
  • CRSP Nasdaq
  • ALHC Nasdaq
  • Market Cap
  • CRSP 3.3B
  • ALHC 3.7B
  • IPO Year
  • CRSP 2016
  • ALHC 2021
  • Fundamental
  • Price
  • CRSP $44.25
  • ALHC $13.96
  • Analyst Decision
  • CRSP Buy
  • ALHC Buy
  • Analyst Count
  • CRSP 15
  • ALHC 11
  • Target Price
  • CRSP $70.62
  • ALHC $17.45
  • AVG Volume (30 Days)
  • CRSP 2.5M
  • ALHC 2.9M
  • Earning Date
  • CRSP 08-04-2025
  • ALHC 07-31-2025
  • Dividend Yield
  • CRSP N/A
  • ALHC N/A
  • EPS Growth
  • CRSP N/A
  • ALHC N/A
  • EPS
  • CRSP N/A
  • ALHC N/A
  • Revenue
  • CRSP $37,675,000.00
  • ALHC $3,001,892,000.00
  • Revenue This Year
  • CRSP $30.25
  • ALHC $43.37
  • Revenue Next Year
  • CRSP $268.62
  • ALHC $26.55
  • P/E Ratio
  • CRSP N/A
  • ALHC N/A
  • Revenue Growth
  • CRSP N/A
  • ALHC 49.12
  • 52 Week Low
  • CRSP $30.04
  • ALHC $7.05
  • 52 Week High
  • CRSP $63.68
  • ALHC $21.06
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 68.22
  • ALHC 37.10
  • Support Level
  • CRSP $42.17
  • ALHC $14.24
  • Resistance Level
  • CRSP $47.04
  • ALHC $15.73
  • Average True Range (ATR)
  • CRSP 2.30
  • ALHC 0.61
  • MACD
  • CRSP 0.47
  • ALHC -0.03
  • Stochastic Oscillator
  • CRSP 74.56
  • ALHC 13.24

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About ALHC Alignment Healthcare Inc.

Alignment Healthcare Inc is a next-generation, consumer-centric platform that is revolutionizing the healthcare experience for seniors through Medicare Advantage plans. These plans are marketed and sold direct-to-consumer, allowing seniors to select the manner in which customers receive healthcare coverage and services on an annual basis. The company combines a technology platform and clinical model for more effective health outcomes.

Share on Social Networks: